ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead

Key Takeaways

• Legal settlements and strategic changes stabilize revenue streams, enhancing future planning and financial clarity for Orexo.
  
• Advancements in product development and strategic partnerships signal potential growth in revenue and net margins.
  
• Supply chain issues, legal uncertainties, and regulatory challenges threaten to delay product launches, increase costs, and impact profitability and revenue streams.

Catalysts

A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.

• The settlement of the Sun Pharmaceuticals litigation provides Orexo with more certainty in maintaining Zubsolv's revenue stream, eliminating the risk of revenue loss from exclusivity issues. This stabilizes future revenue and allows strategic planning for growth.
  
• Stabilizing Zubsolv revenue despite challenges in inventory levels with wholesalers suggests a stable or potentially growing revenue stream, underpinning future revenue stability and earnings.
  
• Progress in clinical trials and favorable data for OX640 suggests potential future growth in revenue from successful product development and market entry, improving future earnings prospects.
  
• Strategic organizational changes, such as transferring Zubsolv IP and manufacturing rights to a wholly-owned subsidiary, could enhance operational efficiency and financial clarity, potentially improving net margins.
  
• The resolution with GAIA on digital assets and the focus on other potential partnerships (e.g., Abera) for the AmorphOX technology indicates a strategic pivot towards high-potential growth areas, potentially increasing future revenues and net margins.

Orexo Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Orexo's revenue will grow by 35.0% annually over the next 3 years.
• Analysts are not forecasting that Orexo will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Orexo's profit margin will increase from -1551.2% to the average GB Pharmaceuticals industry of 19.5% in 3 years.
• If Orexo's profit margin were to converge on the industry average, you could expect earnings to reach SEK 12.5 million (and earnings per share of SEK 0.35) by about April 2029, up from -SEK 403.3 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 125.1x on those 2029 earnings, up from -1.7x today. This future PE is greater than the current PE for the GB Pharmaceuticals industry at 65.3x.
• Analysts expect the number of shares outstanding to grow by 0.58% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.22%, as per the Simply Wall St company report.

Risks

• Supply chain issues with a critical component supplier for OX124 may delay product launch and approval by the FDA, which could postpone potential revenue streams and negatively impact earnings.
  
• Legal uncertainties, such as ongoing negotiations with the Department of Justice, may result in settlements or adverse outcomes, potentially affecting financial stability and increasing operating expenses.
  
• The digital health programs face challenges due to new CMS guidelines requiring FDA registration, needing further investment for clinical evidence. This could impede revenue growth from these assets and require higher expenditures, affecting net margins.
  
• The dependency on Zubsolv as a major revenue contributor, combined with potential pressures from Medicare changes favoring generics, could introduce variability in revenues and affect profit margins if patients shift to alternatives.
  
• Impairments and write-downs of digital assets like Deprexis and Vorvida reflect challenges in obtaining reimbursement and market penetration, potentially limiting expected revenue and forcing restructuring costs, affecting overall profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of SEK38.0 for Orexo based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK64.0 million, earnings will come to SEK12.5 million, and it would be trading on a PE ratio of 125.1x, assuming you use a discount rate of 5.2%.
• Given the current share price of SEK20.2, the analyst price target of SEK38.0 is 46.8% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.